Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Group 1:Inoculation with adenovirus vaccine
Group 2:Inoculation with mRNA vaccine
Group 3:Inoculation with inactivated vaccine
Group 4:Inoculation with protein subunit vaccine
Group 5:Inoculation with saline solution
Sponsors
The Afiliated Hospital of Yunnan University
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1. Subjects aged 18-59 years, no gender limit; 2. Recently received two doses of inactivated COVID-19 vaccine with an interval of 3-5 weeks; 3. Be currently 100-270 days after the second dose of vaccination; 4. Subjects can complete the study process according to the researcher's guidance.
Exclusion criteria
Exclusion criteria: 1. A history of infection with the novel coronavirus; 2. Patients with severe mental and neurological diseases; 3. Patients with the following common diseases (coronary heart disease, hypertension, diabetes, chronic respiratory diseases, tumors, etc.) and poor control; 4. Patients with immune deficiency or immunosuppressive treatment; 5. In the investigator's judgment, the patient has any other ineligible factors for clinical trial participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neutralizing antibody titers;Incidence of adverse events;Cellular immune response to SARS-CoV-2; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serious adverse events and adverse event rates of special concern;Titer multiplication rate of neutralizing antibody;Persistence of neutralizing antibody titers; | — |
Countries
China
Contacts
Public ContactWei Jia
The Affiliated Hospital of Yunnan University
Outcome results
None listed